Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer.

ABSTRACT: In the field of drug repurposing, the use of statins for treating dyslipidemia is considered promising in ovarian cancer treatment based on epidemiological studies and basic research findings. Biomarkers should be established to identify patients who will respond to statin treatment to achieve clinical application. In the present study, we demonstrated that statins have a multifaceted mode of action in ovarian cancer and involve pathways other than protein prenylation. To identify biomarkers that predict the response to statins, we subjected ovarian cancer cells to microarray analysis and calculated Pearson's correlation coefficients between gene expression and cell survival after statin treatment. The results showed that VDAC1 and LDLRAP1 were positively and negatively corre

SUBMITTER: Kobayashi Y 

PROVIDER: S-EPMC8880614 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature